Clinical Trials Directory

Trials / Unknown

UnknownNCT03825848

The Influence of Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy

The Influence of Shunting Left/Right Portal Vein Branch on Post-transjugular Intrahepatic Portosystemic Shunt Hepatic Encephalopathy: a Multicenter Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
130 (estimated)
Sponsor
Shanghai Zhongshan Hospital · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Through a multicenter randomized controlled trial of TIPS to prevent post-hepatitis B cirrhosis of esophagogastric varices, the incidence of hepatic encephalopathy, the rate of stent patency, the incidence of rebleeding and survival in the left and right branches of the portal vein were compared.

Detailed description

The most common cause of cirrhosis in China is hepatitis B virus infection; post-hepatitis B cirrhosis with gastroesophageal variceal hemorrhage is common in clinical practice; recent studies \[14\] found that implantation of 8 mm diameter is compared with the use of 10 mm diameter stents. The membrane stent significantly reduced the incidence of HE after TIPS without affecting the shunt effect. To further evaluate the effect of "left/right branch of shunt portal" on hepatic encephalopathy after TIPS, we intend to conduct the following studies: for individual etiology (post-hepatitis B cirrhosis), the only indication (to prevent recurrent rupture of gastroesophageal varices) ), implanted 8mm diameter Viatorr stent, unified HE evaluation criteria, and stratified multi-center randomized clinical trial study with Child classification, hope to guide TIPS in line with China's national conditions through the high-level evidence-based medical evidence obtained.

Conditions

Interventions

TypeNameDescription
PROCEDUREtrans jugular intrahepatic portal systemic shuntShunting left or right PV branch in the TIPS procedure

Timeline

Start date
2019-06-20
Primary completion
2023-12-31
Completion
2023-12-31
First posted
2019-01-31
Last updated
2019-08-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03825848. Inclusion in this directory is not an endorsement.